Industry
Biotechnology
Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.
Loading...
Open
2.89
Mkt cap
122M
Volume
103K
High
2.92
P/E Ratio
-1.45
52-wk high
8.49
Low
2.84
Div yield
N/A
52-wk low
2.71
Portfolio Pulse from Benzinga Newsdesk
September 04, 2024 | 11:19 am
Portfolio Pulse from Benzinga Newsdesk
August 28, 2024 | 8:15 pm
Portfolio Pulse from Benzinga Newsdesk
August 06, 2024 | 8:46 pm
Portfolio Pulse from Benzinga Newsdesk
June 26, 2024 | 2:33 pm
Portfolio Pulse from Benzinga Newsdesk
June 12, 2024 | 11:17 am
Portfolio Pulse from Benzinga Newsdesk
June 10, 2024 | 11:09 am
Portfolio Pulse from Benzinga Newsdesk
June 05, 2024 | 10:31 am
Portfolio Pulse from Benzinga Newsdesk
June 04, 2024 | 8:09 pm
Portfolio Pulse from Benzinga Newsdesk
May 30, 2024 | 11:01 am
Portfolio Pulse from Benzinga Newsdesk
May 29, 2024 | 11:19 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.